Usefulness of osteoprotegerin in assessing responses to neridronate treatment in Paget's disease of bone

@inproceedings{Ulivieri2006UsefulnessOO,
  title={Usefulness of osteoprotegerin in assessing responses to neridronate treatment in Paget's disease of bone},
  author={Fabio Massimo Ulivieri and Luca Petruccio Piodi and Giorgio Marotta and Daniele Marchelli and C. Commadini and Luca Parravicini and Cesare Verdoia and Paolo Gerundini},
  booktitle={Journal of Orthopaedics and Traumatology},
  year={2006}
}
Osteoprotegerin (OPG) is a protein that inhibits of osteoclastogenesis. The aim this study was to evaluate the response of serum OPG levels to neridronate treatment in patients with Paget's disease of bone resistant to previous therapy. Nine patients (4 men) affected by active Paget’s disease of bone (6 polyostotic, 3 monostotic) not responsive to clodronate were studied. Serum OPG, osteocalcin, total and bone isoenzyme of alkaline phosphatase (AP and BAP, respectively), and urinary… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-8 of 8 references

: benefits of neridronate as a first treatment and in cases of relapse after clodronate

F Pons, L Alvarez, +3 authors A Monegal
1999

Osteoprotegerin ( OPG ) ligand is a cytokine that regulates osteoclast differentiation and activation

DL Lacey, E Timms, +3 authors T Burgess
1998

Paget's disease of bone.

Trends in endocrinology and metabolism: TEM • 1991

Similar Papers

Loading similar papers…